Pluri Inc. Reports Less Than 3 Months Cash Runway, Faces Imminent $27.4M EIB Loan Maturity
PLUR sits 21% above its 52-week low of $2.82.
Summary
Pluri Inc. is facing an acute liquidity crisis with less than three months of cash runway and an imminent $27.4 million EIB loan maturity, raising significant going concern doubts.
Key Events · Legal and Risk Events · PLUR
-
Going Concern Warning Issued
Management estimates the company has sufficient resources for less than three months of operating obligations, raising substantial doubt about its ability to continue as a going concern.
-
Imminent $27.4M EIB Loan Maturity
A $27.4 million loan from the European Investment Bank (EIB) is due on June 1, 2026. Discussions for restructuring are ongoing, but there is no assurance of a favorable outcome.
-
Increased Net Losses and Cash Burn
Net loss for the nine-month period ended March 31, 2026, increased to $19.18 million, up from $15.48 million in the prior year. Net cash used in operating activities also increased to $15.15 million.
-
Recent Capital Injections Insufficient
The company secured $5 million from its Chairman in two private placements (December 2025 and March/April 2026) and sold 23,300 shares for $43,000 under its ATM program, but these funds do not resolve the immediate liquidity challenges.
Analysis · PLUR · Life Sciences
Pluri Inc. has disclosed a critical liquidity crisis, with management estimating less than three months of cash runway from the filing date. This raises substantial doubt about the company's ability to continue as a going concern. Compounding this, a significant $27.4 million loan from the European Investment Bank (EIB) is due on June 1, 2026, with ongoing restructuring discussions offering no certainty of a resolution. Despite recent capital injections totaling $5 million from its Chairman and minor ATM sales, these funds are insufficient to offset the company's increased net losses and cash burn from operations, indicating a severe and immediate financial challenge.
At the time of this filing, PLUR was trading at $3.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.2M. The 52-week trading range was $2.82 to $6.10. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.